Has the FDA ever approved a cannabis-derived medicine?

Yes. Epidiolex, a CBD-based prescription drug for two pediatric seizure disorders, was approved by the FDA in 2018. It is the only cannabis-derived medication on the US market and the regulatory precedent that Roskam's thesis rests on.

Are edibles already used medically?

Yes, in state-licensed medical cannabis programs across more than 40 US states and in countries like Germany, Israel, and Australia. Patients with qualifying conditions use edibles for chronic pain, nausea, spasticity, sleep, and palliative care. Adoption is fragmented but real.

Which brands are positioned for the medical-edibles transition?

1906 and Wana Optimals are the clearest examples, with functional cannabinoid-and-botanical formulations targeting specific use cases. Care By Design is another. The brand-by-brand picture sits in our brands-to-watch coverage and the EdibleRank brand index.

How long does precision dosing take to land in pharma?

Multi-cannabinoid pharmaceutical products are already in clinical trials. The bottleneck is regulatory pathway speed and the cost of phase 3 studies. Roskam's 25-year horizon implicitly assumes federal rescheduling well before 2050.

Arjan Roskam Says Edibles Will Replace Medicine in 25 Years. Is He Right?

The founder of Green House Seed Company and self-proclaimed King of Cannabis has a bold prediction about the future of edibles. Here is the case for and against his thesis.

What does Arjan Roskam predict for the cannabis edibles market?

Roskam predicts that within 25 years cannabis edibles will become a mainstream medical product, properly dosed, delivering THC's therapeutic benefits without the harms of smoking. The Dutch cannabis entrepreneur frames the shift as edibles displacing smoking the way pills displaced tinctures: a format change driven by dosing precision and pharmacokinetic predictability.

He has been making the case in interviews, appearances, and recent Strain Hunters episodes. Edibles as medicine, with recreation as a residual market rather than the main commercial story.

Who is Arjan Roskam

Roskam is one of the most recognized figures in cannabis history. He founded the first Green House coffeeshop in Amsterdam in 1992 and built Green House Seed Company into one of the most awarded cannabis genetics brands in the world, with over 40 Cannabis Cup victories. His Strain Hunters series documented expeditions to find and preserve rare cannabis landraces around the world. He is controversial: critics accuse him of taking credit for genetics he did not develop and of commercializing work done by others. His influence on the global cannabis industry is hard to dispute, and his recent focus on edibles and medical applications suggests he sees the next chapter of cannabis in food, not flower.

Why might edibles actually replace conventional medicine?

The case rests on three trends. Annual edibles market growth of 16 to 22 percent, precision-dosing technology that makes edibles as repeatable as a pharmaceutical pill, and accumulating clinical evidence on cannabinoids for chronic pain, sleep, nausea, and inflammation. Epidiolex proved the FDA pathway is real.

The smoke-free trend is permanent. Nearly half of cannabis consumers already use edibles. And the pharmaceutical industry is watching closely. Epidiolex (a CBD-based drug for two pediatric epilepsies) proved that cannabis-derived compounds can pass FDA scrutiny. More pharmaceutical-grade cannabinoid products are in development, with several multi-cannabinoid combinations currently in phase 2 trials.

What would have to break for the prediction to be wrong?

Schedule I status survives, clinical trials stall, and the industry keeps undermining its credibility with health claims that outrun the data. None of these are unlikely. The 25-year clock depends on regulatory acceleration that has not started in the United States and has only partially started in Europe.

Cannabis remains Schedule I federally in the US, and most countries still classify it as a controlled substance. The FDA has approved exactly one cannabis-derived drug in its history. Clinical trials for cannabinoid medicines are expensive, slow, and complicated by the legal status of the plant. The edibles industry has a credibility problem too: too many brands make health claims that go far beyond what the science supports, which undermines the legitimacy that medical acceptance requires.

Our take

Roskam's direction is right. Edibles are moving toward the medical mainstream, driven by consumer demand, research, and the inherent advantages of oral dosing (precision, duration, no lung damage). Whether it takes 25 years or 40 depends on regulatory willingness and the quality of clinical evidence that accumulates. The brands that treat edibles as a medical delivery format (1906, Care By Design) are ahead of this curve. The brands that treat them as recreational candy will still exist, just outside the medical conversation. Either way, the trajectory Roskam describes is already underway. Direction is settled. The open question is how fast (10 years or 30). For the companion founder read on the same thesis from the supply side, see our piece on Boy Ramsahai and the edibles market, who has been making a nearly identical argument about format change driving category growth. Our own forecast on the same trajectory, scoped to the next five years rather than 25, is in The Future Is Edible.